Comparison of Ticagrelor Versus Clopidogrel on Residual Thrombus Burden During Percutaneous Coronary Intervention: an Optical Coherence Tomography Study
Trial Snapshot
- Phase
- Phase 4
- Status
- Withdrawn
- Locations
- 1
- Primary Endpoint
- Total thrombus burden as measured by the volume of in-stent thrombus quantified by planimetry.
Study Overview
Brief Summary
Subjects with acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study. Subjects that are to be treated clinically with coronary artery stenting will be randomized to receive a loading dose of clopidogrel versus ticagrelor after diagnostic angiography but prior to stenting. Optical coherence tomography (OCT) will be performed after stenting and the presence of blood clots inside the new stent will be measured and compared between the groups.
Detailed Description
Subjects with acute coronary syndromes scheduled for cardiac catheterization will be enrolled in this study. Subjects that are to be treated clinically with coronary artery stenting will be randomized to receive a loading dose of clopidogrel versus ticagrelor after diagnostic angiography but prior to stenting. Optical coherence tomography (OCT) will be performed after stenting and the presence of blood clots inside the new stent will be measured and compared between the groups
Study Design
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel
- Masking
- Single (Outcomes Assessor)
Eligibility Criteria
- Ages
- 18 Years to 79 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patient Characteristics:
- •Males and non-pregnant females > 18 and < 79 years of age presenting with acute coronary syndrome defined as having two of the following criteria:
- •Signs and symptoms consistent with accelerated angina or prolonged angina (lasting greater than 20 minutes) either at rest or with minimal exertion
- •ECG changes indicative of new ischemia
- •Levels of cardiac biomarkers (troponin-T) above the upper limit of the normal range.
- •Patients scheduled to undergo coronary angiography with possible percutaneous coronary intervention (PCI)
- •Lesion Characteristics on Diagnostic Coronary Angiography
- •De novo lesions in native coronary arteries found by diagnostic coronary angiography
- •Angiographic stenosis <100%
- •Reference vessel diameter 2.5 mm - 4.0 mm by visual estimation
Exclusion Criteria
- •General Exclusion Criteria
- •Subjects who are unable or unwilling to sign the informed consent form
- •Subjects being treated with anti-platelet medications other than aspirin prior to diagnostic catheterization including glycoprotein IIb/IIIa inhibitors.
- •Subjects with serious co-morbid conditions that in judgment of the investigator preclude inclusion in this study
- •Subjects with NYHA class III or IV heart failure or known left ventricular ejection fraction < 30%
- •Subjects with an ST elevation myocardial infarction
- •Subjects with hemodynamic or electrical instability (including shock)
- •Subjects diagnosed with severe, non-catheter-related coronary artery spasm
- •Subjects who are or may be pregnant
- •Subjects with known allergies to contrast media
- •Subjects with renal failure as defined by eGFR <
- •History of TIA or stroke < 6 months
- •History of hemorrhagic stroke
- •Hepatic insufficiency defined as liver cirrhosis, AST/ALT/Alkaline Phosphatase greater than 3 times the upper limit of normal or hyperbilirubinemia.
- •Lesion Specific Exclusion Criteria These exclusion criteria apply to the target lesion to be imaged by OCT.
- •Lesion located in the left main coronary artery
- •Lesions that are heavily calcified
- •Lesions where OCT cannot be performed due to technical difficulties
- •Other lesions that the investigator deems inappropriate for the procedure such as sites with excessive tortuosity or low flow by TIMI grade.
- •Lesion in saphenous vein or arterial conduit
Arms & Interventions
Ticagrelor
Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
Intervention: Ticagrelor (Drug)
Ticagrelor
Subjects receive 180 mg of ticagrelor immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
Intervention: Optical Coherence Tomography (Device)
Clopidogrel
Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
Intervention: Clopidogrel (Drug)
Clopidogrel
Subjects receive 600 mg of clopidogrel immediately prior to coronary artery stenting and have optical coherence tomography imaging after the stenting procedure.
Intervention: Optical Coherence Tomography (Device)
Outcomes
Primary Outcomes
Total thrombus burden as measured by the volume of in-stent thrombus quantified by planimetry.
Time Frame: Thrombus burden will be measured at the end of the coronary artery stenting procedure.
The total thrombus burden measured on OCT images will be assessed. The volume of in-stent thrombus will be quantified by planimetry.
Secondary Outcomes
- PRI (platelet reactivity index) as measured by the PLT-VASP assay.(PRI will be measured at the time of OCT image acquistion (which will occur at the end of the coronary artery stenting procedure).)
- P2Y12 Reaction Units as measured by the VerifyNow P2Y12 assay.(P2Y12 will be measured at the time of OCT image acquistion (which will occur at the end of the coronary artery stenting procedure).)
Investigators
Ik-Kyung Jang, MD, PhD
Professor of Medicine
Massachusetts General Hospital